Copyright: ©Author(s) 2026.
World J Nephrol. Sep 25, 2026; 15(3): 120119
Published online Sep 25, 2026. doi: 10.5527/wjn.120119
Published online Sep 25, 2026. doi: 10.5527/wjn.120119
Table 6 Metabolic abnormalities, n (%)
| Abnormality | Total (n = 70) | FTSF (n = 30) | RSF (n = 40) | OR | 95%CI | P value |
| Hypercalciuria | 27 (38.5) | 11 (36.6) | 16 (40.0) | 1.15 | 0.45-2.94 | 0.78 |
| Hyperoxaluria | 21 (30.0) | 9 (30.0) | 12 (30.0) | 1.00 | 0.36-2.77 | 1.00 |
| Hypocitraturia | 16 (22.8) | 7 (23.3) | 9 (22.5) | 0.96 | 0.31-2.98 | 0.94 |
| Low urine volume | 16 (22.8) | 7 (23.3) | 9 (22.5) | 0.96 | 0.31-2.98 | 0.94 |
| Hyperuricosuria | 10 (14.2) | 4 (13.3) | 6 (15.0) | 1.15 | 0.29-4.45 | 0.84 |
| Hyperphosphatemia | 11 (15.7) | 5 (16.7) | 6 (15.0) | 0.88 | 0.26-2.96 | 0.85 |
| Primary hyperparathyroidism | 8 (11.4) | 3 (10.0) | 5 (12.5) | 1.29 | 0.27-6.13 | 0.74 |
| No abnormality | 11 (15.7) | 7 (23.3) | 4 (10.0) | 0.36 | 0.10-1.24 | 0.12 |
- Citation: Navriya SC, Madhav PL, J S, Panwar P, Sharma S, Choudhary GR, Singh M, Bhirud DP, Sandhu AS. Metabolic evaluation in first time and recurrent urinary stone formers: Study from a tertiary care center of India. World J Nephrol 2026; 15(3): 120119
- URL: https://www.wjgnet.com/2220-6124/full/v15/i3/120119.htm
- DOI: https://dx.doi.org/10.5527/wjn.120119